You’re using a public version of DrugChatter with 1 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How has the original aspirin formula been altered for today s advanced antiplatelet drugs?



The original aspirin formula, also known as acetylsalicylic acid, has been modified and advanced to create a new generation of antiplatelet drugs. These modifications have led to the development of drugs with enhanced efficacy, reduced side effects, and specific therapeutic applications.

One of the main advancements in the aspirin formula is the development of enteric-coated aspirin. This formulation is designed to pass through the stomach without dissolving and release the drug in the small intestine, reducing the risk of gastrointestinal side effects such as stomach ulcers and bleeding [1].

Another significant advancement is the creation of modified-release aspirin formulations. These drugs are designed to release the drug slowly over an extended period, providing a steady level of antiplatelet activity and reducing the need for frequent dosing [2].

In addition to these formulation advancements, new antiplatelet drugs have been developed that work in a similar way to aspirin but with different mechanisms of action. For example, clopidogrel (Plavix) and prasugrel (Effient) are thienopyridine derivatives that inhibit the P2Y12 receptor on platelets, preventing platelet activation and aggregation [3].

Ticagrelor (Brilinta) is another antiplatelet drug that works in a different way to aspirin. It is a direct-acting P2Y12 receptor antagonist that does not require metabolic activation, providing a more rapid and consistent antiplatelet effect [4].

In conclusion, the original aspirin formula has been significantly altered and advanced to create a new generation of antiplatelet drugs with improved efficacy, safety, and specific therapeutic applications. These advancements have led to the development of enteric-coated and modified-release aspirin formulations, as well as new drugs such as clopidogrel, prasugrel, and ticagrelor.

Sources:

1. "Enteric Coated Aspirin." Drugs.com, <https://www.drugs.com/aspirin-ec.html>.
2. "Modified-Release Aspirin." Drugs.com, <https://www.drugs.com/mtm/modified-release-aspirin.html>.
3. "Clopidogrel." Drugs.com, <https://www.drugs.com/clopidogrel.html>.
4. "Ticagrelor." Drugs.com, <https://www.drugs.com/ticagrelor.html>.
5. "Aspirin." DrugPatentWatch.com, <https://www.drugpatentwatch.com/drugs/aspirin>.
6. "Clopidogrel." DrugPatentWatch.com, <https://www.drugpatentwatch.com/drugs/clopidogrel>.
7. "Prasugrel." DrugPatentWatch.com, <https://www.drugpatentwatch.com/drugs/prasugrel>.
8. "Ticagrelor." DrugPatentWatch.com, <https://www.drugpatentwatch.com/drugs/ticagrelor>.



Follow-up:   How does aspirin's original formula differ in modern antiplatelets? In what ways was aspirin's formula improved for advanced drugs? What modifications were made to aspirin for today's antiplatelets?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved.